Shots:
- The first patient has been dosed in global P-III AdvanTIG-302 trial evaluating ociperlimab + tislelizumab in 605 naïve patients with locally advanced, unresectable, or metastatic NSCLC whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations across the US, Australia & other countries globally
- The 1EPs of the trial are PFS & OS in the ITT population & 2EPs include safety and other efficacy EPs
- Ociperlimab is currently being investigated in combination with tislelizumab in multiple ongoing trials while the company plans to explore the potential use of ociperlimab in additional settings & indications in its late-stage development program
Click here to read full press release/ article | Ref: Business Wire | Image: Business Times
The post BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer first appeared on PharmaShots.
